TECH Company Profile and Key Details

Q: Who are the executives of TECH?

Mr. Kim KeldermanPres of Diagnostics & GenomicsMr. Gerry AndrosVice President of Sales and MarketingMr. James T. HippelExecutive Vice President of Fin. & Chief Financial OfficerMr. Luca CicchettiManaging DirectorDavid ClairSenior Director of Investor Relations & Corporation Devel.Ms. Brenda S. Furlow J.D.Executive Vice President, Gen. Counsel, Sec. & Chief Compliance OfficerMs. Brenda S. EversonSenior Vice President & Chief HR OfficerMr. Shane BohnenSenior Vice President, Gen. Counsel & Corporation Sec.Mr. Charles R. KummethChief Executive Officer, Pres & DirectorMr. William A. GeistPres of Protein Sciences SegmentMr. Robert M. GavinVice President of Corporation Devel.

NASDAQ : TECH

Bio-Techne

$64.80

-0.68-1.04%

At Close 4:00 PM

58.25

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Bio-Techne Corporation (TECH) stock declined over -1.04%, trading at $64.80 on NASDAQ, down from the previous close of $65.48. The stock opened at $65.48, fluctuating between $64.42 and $65.66 in the recent session.

Stock Snapshot

65.48

Prev. Close

10.14B

Market Cap

64.42

Day Low

122.26

P/E Ratio

0.53

EPS (TTM)

1.43

Cash Flow per Share

65.48

Open

156.45M

Number of Shares

65.66

Day High

97.58%

Free Float in %

12.46

Book Value

1.57M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 10, 2026	65.48	65.66	64.42	64.80	1.57M
Feb 09, 2026	66.07	66.51	64.52	65.48	1.68M
Feb 06, 2026	66.76	67.60	65.85	66.78	1.55M
Feb 05, 2026	68.04	68.57	65.62	65.86	2.69M
Feb 04, 2026	66.69	69.92	61.70	68.67	5.54M
Feb 03, 2026	65.30	66.48	62.86	64.63	3.59M
Feb 02, 2026	63.61	65.29	62.93	65.25	3.25M
Jan 30, 2026	63.26	64.35	62.81	64.09	2.49M
Jan 29, 2026	64.96	65.00	63.05	63.98	2.46M
Jan 28, 2026	67.98	67.98	65.16	65.56	1.79M
Jan 27, 2026	67.53	68.54	67.02	68.23	2.52M
Jan 26, 2026	67.69	68.18	66.94	67.63	1.73M
Jan 23, 2026	69.21	69.24	67.35	68.16	1.9M
Jan 22, 2026	71.80	72.16	69.30	69.65	2.45M
Jan 21, 2026	70.00	71.63	69.18	71.38	2.7M
Jan 20, 2026	67.52	69.74	66.35	69.57	2.28M
Jan 16, 2026	69.84	70.30	68.21	68.67	3.48M
Jan 15, 2026	68.47	70.66	67.98	69.96	3.44M
Jan 14, 2026	66.79	68.50	65.81	68.40	2.74M
Jan 13, 2026	67.13	69.00	63.91	66.36	3.11M

Contact Details

Minneapolis, MN 55413

United States

https://www.bio-techne.com 612 379 8854

About Company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Stock Peers

ARGX

4.92+0.59%

argenx SE$833.16 REGN

-25.37-3.25%

Regeneron Pharmaceuticals, Inc.$754.91 MDGL

-9.43-1.93%

Madrigal Pharmaceuticals, Inc.$478.83 UTHR

0.08+0.02%

United Therapeutics Corporation$473.20 VRTX

-7.39-1.57%

Vertex Pharmaceuticals Incorporated$463.48 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.98+0.93%

Alnylam Pharmaceuticals, Inc.$322.98 PRAX

0.94+0.29%

Praxis Precision Medicines, Inc.$320.48 KRYS

-1.91-0.70%

Krystal Biotech, Inc.$270.70 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Bio-Techne Corporation (NASDAQ:TECH) closed at $64.80 USD, losing -$0.68 (-1.04%) from the previous close of $65.48. The stock is currently mid-range between its 52-week high and low $46.01 and $72.16. With a market capitalization of about $10.14 billion, Bio-Techne Corporation is classified as a large-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 2.06 million shares, in line with its 52-week average. Headquartered in Minneapolis, MN, Bio-Techne Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kim Kelderman, the company employs approximately 3,100 people and listed since February 09, 1989. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.

Technical Performance

TECH has shown sold momentum, gaining 4.51% over the past week and 12.46% over the past quarter, though year-to-date performance is up 18.29%. Short-term trend indicators are bearishly aligned (SMA20 -3.51%, SMA50 2.07%, SMA200 14.2%). The stock’s 14-day RSI is 48.0 (neutral), while the ATR of 2.59 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -10.2% below its high and over 40.84% above its low. Average 10-day trading volume of 2.84 million shares is slightly above the 3-month average of 2.02 million, indicating heightened recent market interest.

Valuation Metrics

Bio-Techne Corporation trades at a P/E ratio of 124.29, slightly above the S&P 500 average, with a price-to-sales ratio of 8.34 and a price-to-book ratio of 4.96 trading at moderately above to book value. The P/FCF stands at 45.43, also above market averages.

Dividend & Fair Value

Bio-Techne Corporation last paid a dividend of 0.32 per share, this equals a trailing yield of roughly 0.42%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $32.10. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Bio-Techne Corporation generated EPS of $0.51 over the past year. Five-year average earnings growth is -20.58%. Wall Street analysts project EPS growth of 9.47% annually over the next five years. The latest quarter delivered EPS of $0.24. The next quarter is forecast at $0.54. Next year's EPS is expected at $18.01. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 9 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $80.00 to $61.00. The high target offers 23.46% upside. The low target suggests -5.86% downside. The mean target is $71.10. This offers 9.72% upside. Bio-Techne Corporation earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -41.86%. The prior quarter beat by 6.0%. Over the last six quarters, Apple has recorded several small beats. These include -3.92% in August 07, 2024.

Shareholding & Insider Activity

Bio-Techne Corporation has 155.55 million shares outstanding. The public float is 153.70 million shares, elevated short interest at 4.29% of float. This equals 5.77 million shares. The short ratio is 2.47 days. Institutional investors hold 107.92% of the float. Insiders own 0.28%. Kummeth Charles R. holds 1.26 million shares, BAUMGARTNER ROBERT V has 44.86 thousand shares and Nusse Roeland has 44.56 thousand shares. Over the past six months, insider transactions show net selling. They sold 34.08 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Bio-Techne generated $1.22B in revenue, or $7.64 per share. Gross margin was 64.80%, operating margin 8.38%, and net profit margin 6.02%. Returns are modest, with ROA at 2.87% and ROE at 3.83%.
On valuation metrics, Bio-Techne trades at a P/E of 124.29, P/S of 8.34 and P/B of 4.96. The current ratio is 4.54 and quick ratio is 3.08. Operationally, the company’s inventory turnover is 2.06 and cash conversion cycle is 232.79 days. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of 0.74.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, Bio-Techne posted revenue of $1.22B, down slightly from $1.16B in the prior quarter. Gross profit was $790.27M (margin 64.80%). Operating income was $102.26M (margin 8.4%). Net income was$73.40M (EPS $0.47).
The company ended the quarter with $162.19M in cash and short-term investments, a total debt of $444.06M, and net debt of $281.87M. Total assets were $2.56B, with equity of $1.92B. Financials further reflected stability, with operating cash flow of $287.56M, free cash flow of $256.55M, and capital expenditures of - $31.01M.

Price Forecast & Outlook

Our AI price prediction model suggests that Bio-Techne Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.04%, with price expected at $62.83 by February 23, 2026, within a range of $60.73 to $64.87 3-Month Outlook: Projected fall of -16.87%, reaching $53.87 by May 08, 2026, with a range of $52.82 to $55.12. 1-Year Outlook: Projected loss of -8.87%, with price at $59.05 by February 09, 2027, within a range of $56.14 to $61.64.

Key Takeaways

Bio-Techne Corporation (NASDAQ:TECH) shares are up 18.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bio-Techne Corporation trading at a premium to the broader market with a P/E of 124.29. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $161.33, suggesting 148.97% upside. Our AI forecast model points to short-term weakness (-3.04% over two weeks), a medium-term fall (-16.87% over three months), and a longer-term loss (-8.87% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Bio-Techne Corporation (TECH) stock price?

Bio-Techne Corporation (NASDAQ: TECH) stock price is $64.80 in the last trading session. During the trading session, TECH stock reached the peak price of $65.66 while $64.42 was the lowest point it dropped to. The percentage change in TECH stock occurred in the recent session was -1.04% while the dollar amount for the price change in TECH stock was - $0.68.

TECH's industry and sector of operation?

The NASDAQ listed TECH is part of Biotechnology industry that operates in the broader Healthcare sector. Bio-Techne Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TECH?

Mr. Kim Kelderman
Pres of Diagnostics & Genomics
Mr. Gerry Andros
Vice President of Sales and Marketing
Mr. James T. Hippel
Executive Vice President of Fin. & Chief Financial Officer
Mr. Luca Cicchetti
Managing Director
David Clair
Senior Director of Investor Relations & Corporation Devel.
Ms. Brenda S. Furlow J.D.
Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer
Ms. Brenda S. Everson
Senior Vice President & Chief HR Officer
Mr. Shane Bohnen
Senior Vice President, Gen. Counsel & Corporation Sec.
Mr. Charles R. Kummeth
Chief Executive Officer, Pres & Director
Mr. William A. Geist
Pres of Protein Sciences Segment
Mr. Robert M. Gavin
Vice President of Corporation Devel.

How TECH did perform over past 52-week?

TECH's closing price is 40.84% higher than its 52-week low of $46.01 where as its distance from 52-week high of $72.16 is -10.2%.

How many employees does TECH have?

Number of TECH employees currently stands at 3,100.

Link for TECH official website?

Official Website of TECH is: https://www.bio-techne.com

How do I contact TECH?

TECH could be contacted at phone 612 379 8854 and can also be accessed through its website. TECH operates from 614 McKinley Place N.E., Minneapolis, MN 55413, United States.

How many shares of TECH are traded daily?

TECH stock volume for the day was 1.57M shares. The average number of TECH shares traded daily for last 3 months was 2.06M.

What is the market cap of TECH currently?

The market value of TECH currently stands at $10.14B with its latest stock price at $64.80 and 156.45M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	3100
Beta	1.48
Sales or Revenue	$1.22B
5Y Sales Change%	0.602%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

TECH Company Profile and Key Details

Bio-Techne

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook